Clinical trial · Interventional
GPC3-CAR-T Cells for the Hepatocellular Carcinoma
The Phase I Efficacy and Safety Clinical Study of GPC3-CAR-T Cells in Hepatocellular Carcinoma Patients
NCT04506983CI-TRIAL-00056518suspendedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Adjust the plan
Summary
Brief summary (as posted)
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of GPC3-CAR-T cells in patients with hepatocellular carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GPC3-CAR-T cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- GPC3-CAR-T cells
- description
- Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells. Tumor markers and GPC3-CAR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 21, day 28).
- interventionNames
- Biological: GPC3-CAR-T cells
Primary outcomes (1)
- measure
- Percentage of adverse events
- timeFrame
- 12months
- description
- Percentage of participants with adverse events.
Secondary outcomes (2)
- measure
- Objective Remission Rate(ORR)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≧18years, gender unlimited. 2. Failure or intolerance after at least first-line treatment. 3. GPC3 positive(IHC) 4. Patients must have at least one target lesion available for evaluation. 5. BCLC B or C. 6. Child-Pugh grade A or B 7. ECOG is 0 or 1 (one week before enrollment.) 8. Estimated life expectancy ≥ 3 months. 9. Functioning of major organs are normal. 10. Women of childbearing age (15-49 years old) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside. 11. Patients who voluntarily sign informed consent and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures. Exclusion Criteria: 1. There are uncontrollable active infections that need systemic treatment. 2. HIV antibody is positive or syphilis antibody is positive. 3. Pregnant or lactating women. 4. hepatic encephalopathy. 5. patients with organ failure: * Heart: NYHA heart function grade IV; * Liver: Grade C that achieves Child-Turcotte liver function grading; * Kidney: kidney failure and uremia; * Lung: symptoms of respiratory failure; * Brain: a person with a disability. 6. It is undergoing systemic hormones therapy. 7. Impact results show that over 50% of the liver is occupied by tumor . 8. Patients who are still in the observation stage of other antitumor drugs 30 days before blood collection. 9. Patients were received other gene therapy products, or are participating in other clinical trials within 4 weeks prior to cell infusion. 10. Abnormal thyroid function ≧Level 3. 11. Active autoimmune diseases require systemic treatment during the first two years of screening. 12. Patients have mental illness or history of drug abuse. 13. Patients are participating in other clinical studies. 14. The researchers found that it was unsuitable for the recipients to be enrolled.
References
Publications (0)
Data not yet available
No reference posted for this study.